RxDoctor Payments Data

Robert Woods, MD

Internal Medicine · Hanford, CANPI 1386697514

Payments from drug & device makers

$433in general payments, 2019–2025

Across 15 payments — averaging $28.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$118
  • Merck$100
  • Novo Nordisk$92
  • Amgen$44
  • Amarin Pharma, Inc.$21
  • Bioventus LLC$17
  • plus $40 from 3 others

What the payments were for

  • Food & beverage$433100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$433 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$46,809
Medicare patients
121
Services billed
562

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin65$66,995
JanuviaSitagliptin Phosphate20$28,458
EliquisApixaban19$20,211
TradjentaLinagliptin14$15,196
FarxigaDapagliflozin Propanediol22$14,797
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$11,148
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$11,078
MyrbetriqMirabegron15$10,293
Janumet XrSitagliptin Phos/Metformin Hcl11$10,015
Lantus SolostarInsulin Glargine,hum.Rec.Anlog68$7,399
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$4,095
Atorvastatin Calcium320$3,521
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$2,775
Rosuvastatin Calcium69$1,861
Losartan Potassium166$1,530

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet Xr$100$38,47331 claims
PfizerEliquis$11$20,21119 claims
GSKTrelegy Ellipta$15$11,14812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Hanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →